Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has been launched in South Korea. Leqembi received the Ministry of Food and Drug Safety, or MFDS, approval in May for treatment in adult patients with mild cognitive impairment due to Alzheimer’s disease, or AD, or mild AD dementia.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- SPY ETF Update, 11/27/2024
- Biogen put volume heavy and directionally bearish
- QQQ ETF Update, 11/26/2024
- VOO ETF Update, 11/25/2024
- SPY ETF Update, 11/22/2024
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
